Figure 2.

Time course changes in the trough dAXP concentrations. Erythrocyte dAXP (A) and blood dAXP (B) at each time point. The target erythrocyte (or blood) dAXP level was set at ≤0.02 µmol/mL. Time of administration indicates the following time points: the 2nd to 5th doses in the dose adjustment period; the 6th to 20th doses in the dose maintenance period; and the 38th to 166th doses in the continuous administration phase. dAXP, deoxyadenosine nucleotide; E1, at the end of the evaluation phase; E2, at the end of the continuous administration phase; SCR, screening.